Meds & supplements › Idarubicin
Medicine
Idarubicin
IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen.
Side effects, and when to stop
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Cardiomyopathy
- Secondary Malignancies
- Severe Local Tissue Necrosis with Extravasation
- Severe Myelosuppression
- Tumor Lysis Syndrome
- Hypersensitivity
Who should not take it
None.
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Idarubicin; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/idarubicin
- APA 7th
sofidex. (2026, August 2). Idarubicin. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/idarubicin
- AMA 11th
Idarubicin. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/idarubicin
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.